At what price per share did the COSM CEO acquire the new shares?

The CEO acquired the new shares at $0.2001 per share . This exchange rate matches the fair market value of Cosmos Health common stock on July 30, 2026, as specified in the Debt Exchange Agreement.

Was the COSM CEO’s share acquisition a cash purchase on the open market?

No, the COSM CEO’s acquisition was a debt-for-equity exchange , not a cash market purchase. The company’s $70,000 debt to him was converted into 349,825 shares at $0.2001 per share under a Debt Exchange Agreement.

Cosmos Health (NASDAQ: COSM) CEO swaps $70K debt for 349,825 shares

Q: What insider transaction did COSM CEO Grigorios Siokas report?

Grigorios Siokas reported acquiring 349,825 shares of Cosmos Health common stock. The shares were obtained at $0.2001 per share through a debt-for-equity exchange that cancelled $70,000 of debt the company owed to him.

Q: Was the COSM insider transaction made under a Rule 10b5-1 trading plan?

The transaction was not indicated as being made under a Rule 10b5-1 trading plan. The filing’s trading-plan checkbox is not marked as applicable to this debt-for-equity exchange by the Cosmos Health CEO.

Filing Impact

(Neutral)

Filing Sentiment

(Positive)

Form Type

Rhea-AI Filing Summary

Siokas Grigorios reported reported purchase transactions in this Form 4 filing.

Cosmos Health Inc. CEO and director Grigorios Siokas acquired 349,825 shares of common stock at $0.2001 per share pursuant to a Debt Exchange Agreement dated July 30, 2026, cancelling $70,000 of debt owed to him.

Following this transaction, he directly holds 14,597,917 shares of Cosmos Health common stock. The exchange rate equals the fair market value of the common stock on July 30, 2026, and the transaction was not indicated as being under a Rule 10b5-1 trading plan.

Insider Trade Summary

Net Buyer: 349,825 shares

Net Buy 1 txn

Insider Siokas Grigorios

Role Chief Executive Officer

Bought 349,825 shs ($70K)

Type	Security	Shares	Price	Value
Purchase	Common Stock, par value $.001 ^F1	349,825	$0.2001	$70K

Holdings After Transaction: Common Stock, par value $.001 — 14,597,917 shares (Direct)

Footnotes (1)

F1. Pursuant to a debt exchange agreement by and between Grigorios Siokas, the Company's CEO and the Company (the "Debt Exchange Agreement"), dated as of July 30, 2026, these shares are Exchange Shares (as defined in the Debt Exchange Agreement) being acquired by Mr. Siokas at the Exchange Rate (as defined in the Debt Exchange Agreement) of $0.2001 per share, the fair market value of the Common Stock on July 30, 2026, in exchange for a total amount of $70,000 in debt the Company owed to Mr. Siokas.

Key Figures

Shares acquired: 349,825 shares Exchange rate: $0.2001 per share Debt exchanged: $70,000 +1 more

4 metrics

Shares acquired 349,825 shares Common stock obtained by CEO Grigorios Siokas in the reported transaction

Exchange rate $0.2001 per share Price used to convert company debt into common stock, equal to fair market value on July 30, 2026

Debt exchanged $70,000 Total amount of company debt to the CEO converted into shares under the Debt Exchange Agreement

Post-transaction holdings 14,597,917 shares Total Cosmos Health common shares directly held by the CEO after the transaction

Key Terms

Debt Exchange Agreement, Exchange Shares, fair market value

3 terms

Debt Exchange Agreement financial

"Pursuant to a debt exchange agreement by and between Grigorios Siokas"

Exchange Shares financial

"these shares are Exchange Shares being acquired by Mr. Siokas"

fair market value financial

"at the Exchange Rate of $0.2001 per share, the fair market value"

The price a willing buyer and a willing seller would agree on for an asset or security when neither is under pressure and both have access to the same information. Think of it as the market’s neutral estimate of what something is worth, like the price two neighbors would settle on for a car after comparing similar listings. Investors care because fair market value guides buying and selling decisions, tax reporting, portfolio valuation, and how accurately company assets are reflected in financial statements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/31/2026 - 11:52 AM Accepted by SEC EDGAR 07/31/2026 - 11:52 AM

FAQ

What insider transaction did COSM CEO Grigorios Siokas report?

Grigorios Siokas reported acquiring 349,825 shares of Cosmos Health common stock. The shares were obtained at $0.2001 per share through a debt-for-equity exchange that cancelled $70,000 of debt the company owed to him.

How many Cosmos Health (COSM) shares does the CEO own after this transaction?

After the reported transaction, Grigorios Siokas directly owns 14,597,917 shares of Cosmos Health common stock. This figure reflects his updated holdings following the acquisition of 349,825 shares via the debt exchange.

Was the COSM insider transaction made under a Rule 10b5-1 trading plan?

The transaction was not indicated as being made under a Rule 10b5-1 trading plan. The filing’s trading-plan checkbox is not marked as applicable to this debt-for-equity exchange by the Cosmos Health CEO.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Siokas Grigorios

(Last)

(First)

(Middle)

5 AG. GEORGIOU STR.

(Street)

PILEA

THESSALONIKI

TK57001

(City)

(State)

(Zip)

GREECE

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cosmos Health Inc. [ COSM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock, par value $.001	07/30/2026	07/30/2026	P⁽¹⁾		349,825	A	$0.2001	14,597,917	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Pursuant to a debt exchange agreement by and between Grigorios Siokas, the Company's CEO and the Company (the "Debt Exchange Agreement"), dated as of July 30, 2026, these shares are Exchange Shares (as defined in the Debt Exchange Agreement) being acquired by Mr. Siokas at the Exchange Rate (as defined in the Debt Exchange Agreement) of $0.2001 per share, the fair market value of the Common Stock on July 30, 2026, in exchange for a total amount of $70,000 in debt the Company owed to Mr. Siokas.

	/s/ Grigorios Siokas	07/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR